Molecular Subtypes Of Breast Cancer Associate With Response To Neoadjuvant Chemotherapy In Breast Cancer

Objective To explore the association between breast cancer molecular subtypes with the response and outcome of breast cancer patients treated with neoadjuvant chemotherapy.Methods121 breast cancer patients treated with neoadjuvant chemotherapy were collected in this study.Molecular subtypes were subdivided as Luminal,HER-2 positive and triple-negative subtype,basing on immunohistochemical results of estrogen receptor(ER),progesterone receptor(PR)and HER-2 status.Correlation between response to neoadjuvant chemotherapy and prognosis with molecular subtypes was mainly estimated.Results Among all 121 cases,69(57.0%)were Luminal subtype,28(23.1%)were HER-2 positive subtype and 24(19.8%)were triple-negative subtype.The ultrasound-evaluated effective rate of neoadjuvant chemotherapy in patients with triple-negative and HER-2 positive and Luminal subtype was66.7%,64.3% and 75.4%,which does not have significant difference(p>0.05).The p CR rate of neoadjuvant chemotherapy in patients with triple-negative and HER-2 positive and Luminal subtype was41.7%,28.6%and16.4%,which has significant difference(p<0.05).After20 months,23 patients had relapses and 15 patients died of breast cancer.The 2-year disease-free survival was 81.6% in whole group.The 2-year disease-free survival was 87.9%,71.4% and 74.1% in Luminal,triple-negative and HER-2 positive group(Log rank p =0.042).The 2-year overall survival was 88.5% in whole group.The 2-year overall survival was 93.8%,81.0% and 81.5%in Luminal,triple-negative and HER-2 positive group(Log rank p =0.051).Conclusion Molecular subtype can predict the pathologic complete response of breast cancer patients treated with neoadjuvant chemotherapy.Compared with Luminal subtype,patients with HER2 positive or triple-negative subtype had increased effective rates but significantly worse survival.